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A B S T R A C T
Background: To evaluate effectiveness, safety, and costs of Lorcaserin vs. phentermine among obese non–surgical
and surgical patients (post bariatric surgery).
Methods: This retrospective study retrieved charts of all patients (January 2013–June 2016) who received
Lorcaserin or phentermine for 3 months. The study assessed anthropometric, glycemic, and lipid changes, as well
as side effects and cost of medications among overweight and obese non-surgical (n= 83) and surgical patients
(n=46). These two patient groups were compared using Chi-square (χ2) and unpaired‘t’ test for qualitative and
quantitative variables respectively.
Results: At 3 months, among the non-surgical group, Phentermine patients had greater percentage of total
weight loss (TWL%) (7.65 ± 8.26 vs. 2.99 ± 3.72%, P= 0.003), and greater BMI reduction (−3.16 ± 3.63 vs.
−1.15 ± 1.53 kg/m2, P= 0.003) than Lorcaserin. Within the surgical group, Lorcaserin patients had sig-
nificantly smaller TWL% (1.86 ± 5.06 vs. 7.62 ± 9.80%, P= 0.012), and smaller BMI reduction
(−0.74 ± 1.80 vs. −3.06 ± 4.08 kg/m2, P=0.012) than Phentermine. Lorcaserin exhibited significant total
cholesterol and LDL improvements only among surgical patients with significant weight reduction (≥5% TW).
Both medications were not associated with glycemic improvements among non-surgical and surgical groups.
Phentermine had slightly more side effects but was less expensive.
Conclusions: Among both patient groups, phentermine was more effective in achieving weight loss. Lorcaserin
showed dyslipidemia improvements only among surgical patients who achieved significant weight reduction.
Anti-obesity medications as part of weight management programs can result in weight loss among non-surgical
and surgical patients, or halt weight regain among surgical patients. This is the first study to evaluate the
effectiveness and safety of two anti-obesity medications (lorcaserin vs. phentermine) among two distinct obese
patient groups, non-surgical and surgical patients.
1. Background
Obesity is a pathophysiological driver of cardiovascular morbidity
and mortality. It is also linked to type 2 diabetes, hypertension and
hyperlipidemia [1,2]. Modest weight loss [≥ 5% Total Weight (TWL
%)] achieved by lifestyle modifications and anti-obesity medications
may improve such obesity-related comorbidities [3,4]. Anti-obesity
medications are indicated for those with BMI ≥27 and≥ 1 co-
morbidity, or those with BMI ≥30 who are not candidates for bariatric
surgery [5]. They may also be a safer alternative to complicated revi-
sional surgeries for bariatric surgery patients who do not achieve
adequate weight loss (5–15% of patients) or regain weight after surgery
(5.7–75% of patients) [6–9]. Lorcaserin and Phentermine are com-
monly used anti-obesity medications: the former is a selective serotonin
2C receptor agonist that increases satiety through the proopiomelano-
cortin system [10]; the latter is an appetite suppressant that inhibits the
reuptake of nor-epinephrine in the hypothalamus [10].
It is important to assess the efficacy of multiple anti-obesity medi-
cations on different patient populations [11,12]. Previous studies as-
sessed only one medication [13–15] or one patient population i.e. non-
surgical (no previous bariatric surgery) or surgical patients (with pre-
vious bariatric surgery and subsequent weight regain/inadequate
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weight loss) [8,16,17]. The one study that compared Lorcaserin vs.
Phentermine among non-surgical and surgical patients reported only
anthropometric outcomes, did not assess cardiovascular outcomes but
side effects or costs [11]. To the best of our knowledge, no study
compared Lorcaserin vs. Phentermine among non-surgical and surgical
patients across a range of cardiovascular and anthropometric outcomes,
side effects, and costs.
Therefore, this retrospective study compared the effectiveness and
safety of Lorcaserin vs. Phentermine at 3 months, among two distinct
groups: non-surgical and surgical patients. The effectiveness measures
included changes in three anthropometric [weight, BMI, total weight
loss% (TWL%)], two glycemic [hemoglobin A1c, fasting blood glucose
(HBA1c, FBS)] and four lipid [(total cholesterol, low density
Lipoprotein, high density lipoprotein, triglycerides (TC, LDL, HDL, TG)]
parameters. The study also evaluated the side effects and costs of both
medications.
2. Material and methods
2.1. Ethics and sittings
The Medical Research Centre at Hamad Medical Corporation (HMC)
approved this retrospective study (IRB, Protocol #17193/17) which
was conducted at the Bariatric Clinic, Hamad General Hospital, Doha,
Qatar.
2.2. Registration
This study is registered with the Research Registry [18] (Research
Registry UIN: research registry 4801.
2.3. Study design
The study is a retrospective record review.
2.4. Procedures and data collection
Using medical charts and electronic records, Lorcaserin or
Phentermine prescription data was retrieved for both patient groups
(non-surgical and surgical). Baseline and 3 months post-treatment va-
lues were retrieved, and change was calculated (value at 3 months
minus baseline value) for the following: Anthropometric parameters
(weight, BMI, and TWL%), TWL%, calculated as: [baseline weight
(before treatment) –follow-up weight (at 3 months)]/baseline
weight× 100; lipid profile parameters (TC, LDL, HDL, TG); and,
Glycemic parameters (FBS, HbA1c). Standard referential values were
used for the assays of these parameters in the blood. Data on reported
side effects included potential gastrointestinal, cardiovascular, and
neurological side effects.
2.5. Inclusion and exclusion criteria
All patients who received Lorcaserin or phentermine for 3 months
during the study period (January 2013–June 2016, N=198) were
eligible to be included. The inclusion criteria included age (≥18 years
old) and BMI (≥30 or≥27 with comorbidities). Patients for whom 3
months follow-up data was unavailable (n= 13), on combination
medications (n= 54), or had endoscopic procedures (intra-gastric
balloon/intra-gastric Botox injection, n=2) were excluded. The re-
maining 129 patients included in the final analysis comprised 83 non-
surgical patients; and 46 surgical patients who were receiving
Lorcaserin or Phentermine due to weight regain (n=34) or inadequate
weight loss (n=12). Weight regain is defined as an increase of> 10 kg
from nadir [19]. Inadequate weight loss is defined as< 50% excess
weight loss (EWL% at 18 months after surgery [20].
2.6. Standard care at the Bariatric Clinic
All patients had initial screening blood tests and baseline ECG. The
choice of anti-obesity medication is individualized based on patient
preference, the drug's contraindications and side effects, as well as their
potential interactions with the patient's existing medication and co-
morbidities. Lorcaserin was given 10mg twice daily, while
Phentermine given 37.5mg once daily. All patients were followed up by
a multidisciplinary team of bariatric physicians, dietitians, and phy-
siotherapists. Surgical patients were additionally followed up by bar-
iatric surgeons at 1, 3, 6, 12 months, and semiannually thereafter. All
patients had follow-up blood tests at 3 months. Dieticians and physical
therapists individually counseled all patients on routine dietary intake
and physical activity. Dietary counseling encouraged patients to follow
a low-calorie high protein (1000–1200 calories/day) diet, and protein
supplements were provided as meal replacement. Physical activity was
based on patient's age, medical condition, physical abilities, and pre-
ference. Patients were encouraged to exercise for 150–300min per
week.
2.7. Statistical analysis
Statistical analysis was performed using the statistical software SPSS
22.0 (SPSS Inc. Chicago, IL). Two-tailed P values were presented with P
values < 0.05 considered statistically significant. Categorical and
continuous values were expressed as frequency (percentage) and
mean ± SD. Descriptive statistics summarized the demographic, an-
thropometric, glycemic, lipid, and clinical characteristics. The
Kolmogorov-Smirnov (K–S) test assessed the data normality. The pri-
mary outcome was to assess and compare the effectiveness (anthropo-
metric, glycemic, lipid, clinical changes) and safety (side effects) of two
anti-obesity medications (Lorcaserin vs. Phentermine) at 3 months
among two independent weight-management groups: non-surgical pa-
tients and surgical patients. Associations between two or more quali-
tative variables were assessed using chi-square (χ2) test and Fisher
Exact test or Yates corrected chi-square, as appropriate. Quantitative
data between the two independent groups was analyzed using unpaired
‘t’ test (Mann Whitney U test for non-normal data).
2.8. Reporting
This study is reported in line with the STROCSS guidelines [21].
3. Results
Table 1 depicts the weight history of the 46 surgical patients, noting
that 40 had laparoscopic sleeve gastrectomy, 4 had Roux-en Y gastric
bypass, and 2 had gastric band (data not presented).
Table 2 depicts the baseline characteristics of the non–surgical and
surgical patients by anti-obesity medication. Significant differences in
Table 1
Weight history of Surgical patients (N=46).
Mean SD
Pre-op weight (kg) 94.30 16.45
Pre-op weight BMI (kg/m2) 37.16 5.73
Nadir weight (kg) 83.98 14.98
Nadir BMI (kg/m2) 32.97 4.93
Surgical weight loss (kg) 34.74 16.27
Total weight loss % (TWL%) 29.58 14.67
Time since surgery (years) 3.5 1.84
Weight nadir to program weight (kg) 10.49 7.81
% weight regain from nadir to program weight 35.08 26.90
Surgical patients included those with inadequate weight loss or weight regain;
SD: standard deviation
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the effects of Lorcaserin vs. Phentermine were observed only among the
non–surgical patients; Lorcaserin patients had lower mean LDL but a
higher proportion of dyslipidemia than Phentermine patients. There
were no other differences across the other variables.
Table 3 shows the changes at 3 months. Within the non–surgical
group, Phentermine patients lost more weight (−8.42 ± 9.69 vs.
−2.98 ± 4.15 kg, P= 0.003), had a greater percentage of weight loss
(7.65 ± 8.26% vs. 2.99 ± 3.72%, P=0.003), and had greater BMI
change (3.16 ± 3.63 vs. 1.15 ± 1.53 kg/m2, P=0.003) than Lorca-
serin patients. On the other hand, Lorcaserin patients had significantly
lower mean LDL than Phentermine patients, although such significant
differences were already present at baseline. No other significant
changes were observed in the non-surgical group. Within the surgical
group, Lorcaserin patients had significantly less weight reduction
(−1.81 ± 4.54 vs. −7.68 ± 10.32 kg, P=0.012), smaller percen-
tage of weight change (1.86% vs. 7.62%, P=0.012), and lower re-
duction in BMI (−0.74 ± 1.80 vs. −3.06 ± 4.08 kg/m2, P=0.012)
than Phentermine patients. There were no other significant changes
observed between the two anti-obesity medications in the surgical
group.
Table 4 illustrates the analysis of the changes at 3 months for the
subgroup of non–surgical and surgical patients who had significant
weight loss (≥5% of TW). Only among the surgical group, Lorcaserin
patients had reduction in TC (−0.85 ± 0.51 vs. −0.02 ± 0.33mmol/
l, P= 0.003) and LDL (0.57 ± 0.39 vs. 0.02 ± 0.25mmol/l,
P= 0.008) levels when compared with Phentermine patients. There
were no other significant changes observed between Phentermine vs.
Lorcaserin in the surgical group or non-surgical group in terms of lipid
profile or glycemic parameters.
In terms of safety, Table 5 shows that the most common reported
side effects were palpitations for Phentermine (6%) and headache for
Lorcaserin (5.9%). Table 6 depicts the comparative cost analysis of
Phentermine vs. Lorcaserin. For each patient, a 30-day supply of
Phentermine costs USD 18.28 and USD 283.82 for Lorcaserin [22].
Based on a 3-months treatment regime, savings of USD 49280.76 would
have been achieved had Phentermine been prescribed to all Lorcaserin
patients (assuming none of the Lorcaserin patients had any contra-
indications to Phentermine). Extrapolating further, Table 6 also shows
the potential savings that could have resulted when applying the costs
of the two anti-obesity medications to the findings of Grabarczyk et al.
in a recent larger study of a longer duration (12 months, 298 patients)
[12]. If Grabarczyk et al. would have prescribed Phentermine to all
their Lorcaserin patients for the same 12-month period [12], their po-
tential savings would have amounted to USD 949571.
Table 7 summarizes all the study findings among non–surgical and
surgical patients.
Table 2
Baseline characteristics of the patient groups by anti-obesity medication.
Demographic and Anthropometric Non-surgical patients* Surgical patients**
Phentermine Lorcaserin Phentermine Lorcaserin
(N=48) (N=35) (N=19) (N=27)
Mean ± SD Mean ± SD P Mean ± SD Mean ± SD P
Age, y 40.91 ± 10.96 42.05 ± 10.71 0.638 45.05 ± 9.44 43.81 ± 10.39 0.682
Gender, N (%) 0.179 0.772
Male 11 (22.9) 4 (11.4) 1 (5.3) 2 (7.4)
Female 37 (77.1) 31 (88.6) 18 (94.7) 25 (92.6)
Height, m 1.61 ± 0.08 1.59 ± 0.08 0.172 1.59 ± 0.07 1.58 ± 0.07 0.695
Weight, kg 100.20 ± 20.88 94.55 ± 20.83 0.227 94.84 ± 18.18 93.91 ± 15.46 0.852
BMI, kg/m2 38.27 ± 7.57 37.17 ± 7.32 0.512 36.98 ± 5.27 37.28 ± 6.13 0.859
EW, kg 34.53 ± 19.74 30.95 ± 18.77 0.409 30.93 ± 14.83 30.68 ± 14.81 0.956
Glycemic
FBS, mmol/l 6.02 ± 3.89 5.69 ± 1.69 0.640 4.78 ± 0.84 4.70 ± 0.75 0.728
HbA1c, % 6.06 ± 1.50 5.60 ± 0.75 0.110 5.64 ± 0.86 5.50 ± 0.47 0.494
Lipid profile, mmol/l
TC 4.96 ± 0.74 4.63 ± 0.78 0.060 5.14 ± 0.99 5.11 ± 0.70 0.916
LDL 3.08 ± 0.67 2.73 ± 0.65 0.021 3.08 ± 0.85 3.11 ± 0.60 0.886
HDL 1.27 ± 0.30 1.35 ± 0.34 0.285 1.61 ± 0.42 1.43 ± 0.27 0.098
TG 1.43 ± 1.21 1.25 ± 0.53 0.403 0.97 ± 0.42 1.17 ± 0.50 0.186
Clinical, n (%) n (%) n (%) P n (%) n (%) P
Prediabetes 0.061 0.225
Yes 9 (18.8) 13 (37.1) 0 (0) 2 (7.4)
No 39 (81.3) 22 (62.9) 19 (100) 25 (92.6)
Diabetes 0.425 0.175
Yes 9 (18.8) 4 (12.1) 6(31.6) 4 (14.8)
No 39 (81.3) 29 (87.9) 13 (68.4) 24 (85.2)
Hypertension 0.674 0.928
Yes 9 (18.8) 5 (15.2) 3 (15.8) 4 (14.8)
No 39 (81.3) 28 (84.8) 16 (84.2) 25 (85.2)
Dyslipidemia 0.010 0.321
Yes 9 (18.8) 15 (45.5) 4 (21.1) 9 (34.6)
No 39 (81.3) 18 (54.5) 15 (78.9) 17 (65.4)
Patient group: on medical weight management, *without previous bariatric procedure or **with previous bariatric procedure, SD standard deviation, BMI Body Mass
Index, EW excess weight, FBS fasting blood sugar, HBA1c glycosylated hemoglobin A1c, TC Total Cholesterol, LDL low density Lipoprotein, HDL high density
lipoprotein: high density lipoprotein, TG triglycerides.
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4. Discussion
Studies on the effectiveness and safety of anti-obesity medications
for weight loss and cardiovascular risk factors remain limited [15]. The
current study compared the effectiveness and safety of Phentermine vs.
Lorcaserin among non-surgical and surgical patients. The main findings
are that at 3 months, among the non-surgical group, Phentermine
patients significantly lost more weight, and had higher TWL% and BMI
change when compared to Lorcaserin patients. Further analysis of the
patient subgroup that achieved significant weight reduction (≥5% TW)
showed that only in the surgical group, Lorcaserin patients had sig-
nificant changes in TC and LDL when compared to Phentermine.
However, the weight reductions observed with both anti-obesity med-
ications were not associated with any significant improvement in
Table 3
Changes at 3 months by patient group.
Non-surgical patients* Surgical patients**
Phentermine (N=48) Lorcaserin (N=35) Phentermine (N=19) Lorcaserin (N=27)
Anthropometric Mean ± SD Mean ± SD P Mean ± SD Mean ± SD P
Weight, kg 91.78 ± 16.90 91.56 ± 19.36 0.958 87.16 ± 18.03 92.06 ± 15.24 0.322
Change from Baseline, kg a 8.42 ± 9.69 2.98 ± 4.15 0.003 7.68 ± 10.32 1.81 ± 4.54 0.012
TWL%b 7.65 ± 8.26 2.99 ± 3.72 0.003 7.62 ± 9.80 1.86 ± 5.06 0.012
BMI, kg/m2 35.11 ± 6.39 36.02 ± 6.94 0.537 33.92 ± 4.66 36.54 ± 5.90 0.114
Change from Baseline 3.16 ± 3.63 1.15 ± 1.53 0.003 3.06 ± 4.08 0.74 ± 1.80 0.012
TWL (%)
< 5% 11(22.9) 24(68.6) <0.0001 5(26.3) 13 (48.1) 0.135
5–9.9% 10 (20.8) 3 (8.6) 0.129 4 (21.1) 7 (25.9) 0.703
10–19.9% 14 (29.2) 4 (11.4) 0.493 3 (15.8) 1 (3.7) 0.152
≥ 20% 8 (8.3) 0 (0) 0.080 3 (15.8) 0 (0) 0.033
Weight gain 6 (12.5) 4 (11.4) 0.882 4 (21.1) 6 (22.2) 0.925
Glycemic
FBS, mmol/l 5.87 ± 2.62 5.51 ± 1.20 0.541 4.59 ± 0.62 4.88 ± 0.78 0.247
Change from Baseline 0.29 ± 2.29 0.52 ± 1.50 0.679 −0.03 ± 0.81 −0.28 ± 0.52 0.317
HBA1C % 5.94 ± 1.19 5.61 ± 0.88 0.279 5.59 ± 0.70 5.42 ± 0.60 0.477
Change from Baseline 0.15 ± 0.37 0.10 ± 0.77 0.797 0.15 ± 0.52 0.10 ± 0.23 0.720
Lipid profile, mmol/l
TC 4.91 ± 0.72 4.66 ± 0.69 0.189 5.03 ± 1.10 4.81 ± 0.77 0.507
Change from Baseline 0.22 ± 0.62 −0.00 ± 0.80 0.231 −0.01 ± 0.53 0.30 ± 0.60 0.123
LDL 3.09 ± 0.81 2.62 ± 0.56 0.018 2.95 ± 0.90 2.85 ± 0.61 0.698
Change from Baseline 0.15 ± 0.79 0.03 ± 0.68 0.567 0.04 ± 0.38 0.19 ± 0.50 0.360
HDL 1.38 ± 0.49 1.36 ± 0.38 0.873 1.61 ± 0.33 1.38 ± 0.29 0.041
Change from Baseline −0.08 ± 0.46 0.03 ± 0.30 0.246 −0.03 ± 0.22 0.08 ± 0.12 0.084
Triglycerides 1.28 ± 0.78 1.30 ± 0.61 0.924 0.91 ± 0.44 1.29 ± 0.64 0.063
Change from Baseline 0.14 ± 0.65 0.06 ± 0.49 0.590 0.02 ± 0.29 −0.06 ± 0.41 0.474
Patients: on medical weight management *without previous bariatric procedure or **with previous bariatric procedure, amean value at 3 months minus mean
baseline value, bchange from baseline divided by baseline weight x 100, TWL% percentage of total body weight loss, BMI body mass index, FBS fasting blood sugar,
HbA1c glycosylated hemoglobin A1C, TC Total Cholesterol, LDL low density Lipoprotein, HDL high density lipoprotein, TG triglycerides.
Table 4
Changes at 3 months for patients with significant weight loss ≥5% of TW.
Non-surgical patients* Surgical patients**
Phentermine (N=31) Lorcaserin (N=7) Phentermine (N=10) Lorcaserin (N=8)
Glycemic Mean Mean ± SD Mean ± SD P Mean ± SD Mean ± SD P
FBS, mmol/l 5.88 ± 2.62 5.20 ± 1.21 0.544 4.61 ± 0.62 4.87 ± 0.51 0.402
Change from Baseline 0.58 ± 2.60 0.68 ± 1.13 0.930 0.22 ± 0.38 −0.04 ± 0.53 0.022
HBA1C % 6.02 ± 1.26 5.52 ± 0.60 0.404 5.56 ± 0.50 5.31 ± 0.38 0.309
Change from Baseline 0.08 ± 0.33 0.06 ± 0.59 0.906 0.02 ± 0.33 0.18 ± 0.16 0.311
Lipid profile, mmol/l (mean ± SD)
TC 4.88 ± 0.77 4.77 ± 0.64 0.756 5.12 ± 1.05 4.50 ± 0.53 0.188
Change from Baseline 0.37 ± 0.69 0.36 ± 0.32 0.966 0.02 ± 0.33 0.85 ± 0.51 0.003
LDL 2.97 ± 0.74 2.60 ± 0.40 0.303 3.07 ± 1.00 2.65 ± 0.57 0.347
Change from Baseline 0.35 ± 0.63 0.40 ± 0.74 0.897 0.02 ± 0.25 0.57 ± 0.39 0.008
HDL 1.28 ± 0.26 1.29 ± 0.25 0.997 1.52 ± 0.23 1.30 ± 0.23 0.104
Change from Baseline −0.003 ± 0.29 0.01 ± 0.20 0.902 0.06 ± 0.18 0.06 ± 0.09 0.964
Triglycerides 1.40 ± 0.91 1.64 ± 0.98 0.615 0.96 ± 0.50 1.21 ± 0.67 0.430
Change from Baseline 0.16 ± 0.61 −0.03 ± 0.61 0.540 0.08 ± 0.31 0.09 ± 0.21 0.913
Patient group: on medical weight management *without previous bariatric procedure or **with previous bariatric procedure, FBS fasting blood sugar, HbA1c
glycosylated hemoglobin A1C, TC Total Cholesterol, LDL low density Lipoprotein, HDL high density lipoprotein, TG triglycerides.
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glycemic control in both groups. Both medications were well tolerated
with few side effects. Phentermine was less expensive than Lorcaserin
(savings= $796.62 USD per 3-month regime/patient).
In terms of anthropometric parameters among the non-surgical
group, the current study found that at 3 months, Phentermine patients
exhibited significantly higher TWL% when compared with Lorcaserin
(7.65% vs. 2.99%, P= 0.03). This is contrary to other studies that re-
ported similar TWL% (3.6%) between Lorcaserin and Phentermine
[12]. Most Phentermine studies are small and outdated (e.g. [23,24]).
One recent study used a diffuse controlled release Phentermine for-
mulation on a small sample (n=37) and reported that 95.8% of their
patients achieved WL≥5%. That was greater than the 58.3% observed
by the current study (data not presented), which is likely explained by
the diffuse controlled release formulation used [25]. As for Lorcaserin
patients, 8.6% lost ≥5% and 11.4% lost ≥10% of TW. These results are
lower than other studies (47.3% lost ≥5% and 22.6% lost ≥10% of TW
respectively) [26], probably due to their longer study duration (1 year)
[25], or generally due to psycho-behavioral and nutritional factors
[27]. As for the anthropometric parameters among the surgical group,
at 3 months significantly more Phentermine patients (31.6%) achieved
≥10% TWL% compared to Lorcaserin patients (3.7%) patients. These
findings support other research suggesting that Phentermine could be
useful among surgical patients with weight regain [8,19]. However, we
are unable to directly compare the Lorcaserin findings with other stu-
dies because other studies did not report weight loss outcomes in-
dividually for Lorcaserin [11,28]. In terms of surgical weight history,
the average time for weight regain post bariatric surgery was shorter for
patients in the current study for weight regain after (3.5 years) com-
pared with other reports (6.1 years) [11] . Despite the shorter duration,
the average weight regain in the current study was 35% of the
minimum weight loss achieved post-surgery, similar to the 34% re-
ported by others [11]. This is likely attributed to several factors: tech-
nical/anatomical, physiological, psychosocial, and lifestyle/behaviour
[9].
In terms of lipid profile among the non-surgical group, at 3
months, both anti-obesity medications did not lead to significant
Table 5





Headache 0 (0) 3 (5.9)
Blurred Vision 0 (0) 1 (2)
Dizziness 1 (1.5) 1 (2)
Dry Mouth 0 (0) 0 (0)
Constipation 2 (3) 0 (0)
Drowsiness 1 (1.5) –
Depression 0 (0) 0 (0)
Numbness 0 (0) –
Restlessness 0 (0) –
Insomnia 3 (4.5) –
Nervousness 1 (1.5) –
Palpitation 4 (6) –
All cells represent N (%), — not applicable.
Table 6
Comparative cost analysis by anti-obesity medication.
Variable Current study* (3 months) Previous study Grabarczyk** (12 months)
Lorcaserin Phentermine Saving Used
Lorcaserin
If used Phentermine Saving
Total number of patients 62 67 – 298 298 –
Duration of treatment 3m 3m – 12m 12m –
Cost per month per patient 283.82 18.28 265.54 283.82 18.28 265.54
Total cost per patient 851.46 for 3m 54.84 for 3m 796.62 for 3m 3405.84 for 12m 219.36for 12m 3186.48
Total cost for period (USD) a 52790.52 3509.76 49280.76 1.015M 65369.28 949571.04
*Calculated for current study period (3 months), ** Calculated for their prescription period (1 year), All costs presented in USD, — not applicable, m months, M:
million, a: cost for 62 patients.
Table 7
Summary of Changes at 3 months by patient group.
Non-surgical patients* Surgical patients**
Parameter Phentermine vs.Lorcaserin (48 vs.35) Phentermine vs.Lorcaserin (19 vs.27)
Anthropometric mean (SD)
Weight
Actual weight No difference No difference
Weight changea and TWL%b Phentermine associated with greater weight reduction and more TWL% Phentermine associated with greater weight reduction and more
TWL%
BMI
BMI level No difference No difference
BMI change Phentermine associated with more BMI reduction Phentermine associated with more BMI reduction
TWL (%) No difference at all levels of TWL%, except Lorcaserin associated with
higher percentages of patients with lower (< 5%) TWL%
No difference at all levels of TWL%, except Phentermine associated
with higher percentages of patients with higher (≥20%) TWL%
Weight gain No difference No difference
Glycemic (FBS, HBA1C) No difference in FBS or HBA1C levels No difference in FBS or HBA1C levels
Lipids (TC, LDL, HDL, TG)
Actual levels No difference, except Lorcaserin associated with lower LDL level No difference except Phentermine associated with higher HDL level
Level Change No difference for all lipids No difference for all lipids
Side effects Phentermine slightly more Lorcaserin slightly more
Cost Phentermine less expensive Phentermine less expensive
*Without previous bariatric procedure, **With previous bariatric procedure, amean value at 3 months minus the mean baseline value, bchange from baseline divided
by the baseline weight x 100, TWL% percentage of total body weight loss, BMI Body Mass Index, FBS fasting blood sugar, HbA1c glycosylated hemoglobin A1C, TC
Total Cholesterol, LDL low density Lipoprotein, HDL high density lipoprotein, TG triglycerides.
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improvement. This observation agrees with other studies on
Lorcaserin [15], yet it contradicts reports of other research on Phen-
termine where improvements in lipid profile were observed [13,25].
The findings of weight reduction without significant improvement in
lipid profile for both anti-obesity medications may be a result of the
short duration of the current study. Studies with longer duration
would be beneficial in this regard. As for the lipid profile within the
surgical group, both anti-obesity medications showed no significant
change at all levels of TWL%. However, analyzing the subgroup of
patients who achieved clinically significant TWL% (≥5%) showed
that Lorcaserin resulted in greater reduction of TC and LDL compared
to Phentermine (0.85 ± 0.51 vs. 0.02 ± 0.33mmol/l, P= 0.003 and
0.57 ± 0.39 vs. 0.02 ± 0.25mmol/l, P= 0.008, respectively). These
findings support that modest weight loss [≥ 5% Total Weight (TWL
%)] may improve obesity-related comorbidities [3,4].
As for glycemic control in the non-surgical group, at 3 months, both
anti-obesity medications showed no significant differences in FBS and
HbA1c levels. Such lack of glycemic improvement for Phentermine
agrees with other studies where phentermine did not improve FBG at 3
months post treatment [13]. However, our observation of the lack of
glycemic improvement for Lorcaserin is not consistent with other re-
search probably due to their large sample of prediabetic (n= 6136) and
diabetic (n= 351) patients [15,29]. A larger sample size may have
allowed the current study to detect such findings. In terms of glycemic
control in the surgical group, both Phentermine and Lorcaserin patients
exhibited no significant improvements in FBS and HBA1C. This is
supportive of a study where Phentermine resulted in no change in the
number of diabetes medications suggesting no clinical improvement
(albeit without measuring biochemical data e.g., HBA1c) [8]. To the
best of our knowledge, no data exists on Lorcaserin's effect on cardio-
vascular risk factors among bariatric surgical patients with weight re-
gain. Future research should address this gap as well as the underlying
physiology.
In terms of side effects, a greater percentage of Phentermine patients
reported side effects when compared to Lorcaserin patients (18 vs.
9.9%). Lorcaserin was generally well tolerated, with minimal side ef-
fects (most frequently headache 5.9%) in agreement with other re-
search [15]. As for Phentermine, palpitations and insomnia were the
most common, agreeing with other papers that reported insomnia as the
most common side effect [13]. These findings are therefore consistent
with this class of sympathomimetic drugs, where central excitation may
manifest clinically as insomnia or increased heart rate [30]. This has
contributed to the limited use of Phentermine among cardiovascular
disease patients [10].
Cost data should be considered when selecting anti-obesity medi-
cations. In countries where anti-obesity medications are not covered by
medical insurance, and drug cost is an expensive burden on patients,
Phentermine may be a cheaper alternative to other expensive anti-
obesity medications [28]. In countries with Universal health coverage,
the high costs of some anti-obesity medications could burden the
system. It is important to note that Phentermine is approved only for
short-term use and probably not ideal for the management of a chronic
condition such as obesity where the discontinuation of treatment might
lead to weight regain. However, Phentermine intermittent and con-
tinuous therapies may result in the same weight loss accordingly,
Phentermine intermittent regimens would be equally effective and
would comply with the prescribing guidelines [21]. In contrast, Lor-
caserin, although more expensive, is approved for long-term treatment
of obesity.
This study has limitations. The relatively small sample size was
because many patients were on combination pharmacotherapy (hence
excluded) or due to unavailable data which is a limitation of retro-
spective studies. A longer follow-up would have enabled the current
study to assess weight maintenance beyond 3 months. Moreover, re-
viewing blood pressure values as an indicator of cardiovascular risk
would have been useful. The nutritional outcomes of anti-obesity
medications (e.g. on hunger, food craving and satiety scores) were not
assessed which are important factors in predicting weight gain.
Likewise, assessment of the broader psych-behavioral, demographic,
and environmental parameters could have shed more light on the
characteristics associated with weight loss [29]. Future research would
benefit from exploring these limitations. Nevertheless, the study has
many strengths and has addressed identified gaps in the literature; we
assessed the effectiveness and safety of Phentermine vs. Lorcaserin in
real world practices, among obese non-surgical and surgical patients,
using a wide range of anthropometric, lipid, glycemic, side effects and
cost data. Such holistic approach has been less explored and studies
pertaining to this variety of outcomes remain very limited.
5. Conclusion
At 3 months, among the non-surgical group, Phentermine patients
had greater percentage of total weight loss (TWL%), and greater BMI
reduction than Lorcaserin. Within the surgical group, Lorcaserin patients
had significantly smaller TWL%, and BMI reduction than Phentermine.
Among non-surgical and surgical patients, weight loss of ≥20% was only
achieved with Phentermine. Lorcaserin exhibited significant TC and LDL
improvements only among surgical patients with significant weight re-
duction (≥5% TW). Both medications were not associated with any
glycemic (FBS, HbA1c) improvements among non-surgical and surgical
patients. Using Phentermine instead of Lorcaserin when there is no
contraindication could result in large savings, albeit with slightly more
side effects. For non-surgical patients, using anti-obesity medications as
part of a comprehensive multidisciplinary medical weight management
program can result in weight loss. For surgical patients, anti-obesity
medications can halt or reverse weight regain.
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